CoVasc – SARS CoV-2 in heart and vascular inflammation

Learn more about the CoVasc consortium

Acute pulmonary inflammation is the central feature of COVID-19, however, patients with severe COVID-19 can also suffer from cardiovascular and neurological complications such as microvascular thrombosis, cardiac injury, and loss of taste and smell. The mechanisms how the virus SARS-CoV-2 affects heart and vascular cells, including those of the blood-brain-barrier, are subject to current research performed in sitem-insel’s high-level biosafety laboratory.

The CoVasc consortium, a group of 4 research project leaders and 10 project partners, connects experts in heart research, vascular biology and neuroimmunology as well as in virology. Together they investigate how and if heart and vascular cells are prone to be infected by the SARS-CoV-2.

Find out more about the project here:

Department for BioMedical Research (DBMR) (

NRP 78 "Covid-19" (

In cooperation with:

Swiss National Science Foundation (SNSF) (

Universität Bern (